REGENXBIO Inc. $RGNX Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its position in REGENXBIO Inc. (NASDAQ:RGNX) by 64.5% in the 4th quarter, Holdings Channel reports. The firm owned 1,160,380 shares of the biotechnology company’s stock after buying an additional 454,977 shares during the period. Assenagon Asset Management S.A.’s holdings in REGENXBIO were worth $16,709,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Diversified Trust Co. grew its stake in REGENXBIO by 24.3% during the 4th quarter. Diversified Trust Co. now owns 13,378 shares of the biotechnology company’s stock worth $193,000 after buying an additional 2,615 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in REGENXBIO by 13.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 44,429 shares of the biotechnology company’s stock valued at $630,000 after buying an additional 5,115 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of REGENXBIO by 4.8% in the third quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock valued at $38,959,000 after acquiring an additional 185,223 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in shares of REGENXBIO by 33.9% in the third quarter. CANADA LIFE ASSURANCE Co now owns 14,510 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 3,671 shares during the period. Finally, Mariner LLC grew its position in shares of REGENXBIO by 150.4% during the third quarter. Mariner LLC now owns 32,306 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 19,402 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on RGNX shares. UBS Group reaffirmed an “overweight” rating and issued a $18.00 target price on shares of REGENXBIO in a report on Tuesday, February 10th. HC Wainwright decreased their price target on shares of REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Leerink Partners lifted their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Robert W. Baird set a $27.00 price objective on shares of REGENXBIO in a research note on Tuesday, February 10th. Finally, Chardan Capital decreased their target price on shares of REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and an average price target of $27.50.

Insiders Place Their Bets

In other REGENXBIO news, insider Steve Pakola sold 5,124 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total value of $53,033.40. Following the completion of the transaction, the insider owned 247,926 shares in the company, valued at approximately $2,566,034.10. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.79% of the stock is owned by corporate insiders.

REGENXBIO Trading Down 2.4%

Shares of RGNX opened at $8.26 on Friday. The stock’s 50 day moving average is $9.88 and its two-hundred day moving average is $11.37. REGENXBIO Inc. has a twelve month low of $5.03 and a twelve month high of $16.19. The firm has a market capitalization of $426.30 million, a PE ratio of -2.20 and a beta of 1.08.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). The business had revenue of $30.34 million for the quarter, compared to analysts’ expectations of $45.48 million. REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%. On average, sell-side analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.